Prazer Therapeutics Inc.

Prazer Therapeutics Inc. is focused on developing innovative therapeutics for refractory diseases, utilizing proprietary technologies to target previously undruggable protein aggregates and inflammatory conditions, enhancing patient care. Prazer Therapeutics Inc. specializes in creating novel treatments for complex diseases through its proprietary technologies.

Founded in 2019, the company operates out of Seoul, South Korea. The firm has successfully completed 2 deals, including a Series B funding round in April 2025, raising KRW 29 billion led by Johnson & Johnson Innovation, with participation from several other investors. The founder has a history of entrepreneurship in the biotechnology sector, although specific details about previous ventures are not provided. Prazer Therapeutics specializes in the development of innovative therapeutics aimed at treating refractory diseases, focusing on drugging previously undruggable targets.

The company’s core product offerings center around its proprietary SPiDEM™ technology, designed to degrade target proteins through small molecules. These small molecules target protein aggregates and inflammatory proteins, with applications in neurodegenerative and refractory inflammatory diseases. The SPiDEM™ technology is also being utilized to create therapeutics for viral diseases by targeting host factors, primarily serving patients with hard-to-treat conditions and healthcare providers, although specific geographical markets remain undisclosed. The revenue generation model of Prazer Therapeutics is based on collaborative partnerships and potential licensing agreements for its SPiDEM™ technology and related therapeutics.

The company engages in business-to-business transactions with pharmaceutical companies and research institutions, deriving revenue from milestone payments, royalties, and research collaborations that fund ongoing development efforts. Specific financial figures and pricing plans have not been disclosed, but the company’s strategic focus on therapeutic advancements positions it to leverage the growing demand for effective treatments in the healthcare market. In April 2025, Prazer Therapeutics Inc. raised KRW 29 billion in Series B funding led by Johnson & Johnson Innovation, aimed at accelerating the development and commercialization of new drugs through research and collaboration with pharmaceutical companies.

The company plans to design and launch additional products leveraging the SPiDEM™ technology, with a view of expanding into new markets. Specific regions targeted for expansion are yet to be disclosed, with efforts focused on addressing unmet medical needs. The recent funding will facilitate the enhancement of their research initiatives and collaboration with other industry players.